Alnylam Pharmaceuticals, Inc. Share Price
ALNYAlnylam Pharmaceuticals, Inc. Stock Performance
Open $393.50 | Prev. Close $391.17 | Circuit Range N/A |
Day Range $388.71 - $399.26 | Year Range $205.97 - $494.83 | Volume 82,189 |
Average Traded $391.96 |
Alnylam Pharmaceuticals, Inc. Share Price Chart
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
15-Dec-25 | $393.80 | $391.41 | -1.52% |
12-Dec-25 | $408.22 | $397.46 | -3.72% |
11-Dec-25 | $404.42 | $412.81 | +2.12% |
10-Dec-25 | $415.69 | $404.24 | -2.63% |
09-Dec-25 | $430.89 | $415.17 | -3.45% |
08-Dec-25 | $447.00 | $430.00 | -6.13% |
05-Dec-25 | $470.18 | $458.06 | -1.58% |
FAQs on Alnylam Pharmaceuticals, Inc. Share Price
Can I buy Alnylam Pharmaceuticals, Inc. shares in India?
What is the share price of Alnylam Pharmaceuticals, Inc.?
What is the 5 year returns of Alnylam Pharmaceuticals, Inc.?
What are the high & low stock price of Alnylam Pharmaceuticals, Inc. today?
What is the 52-week high and low of Alnylam Pharmaceuticals, Inc. stock?